Pipeline Watch: Phase III Studies of CSL112 And RT-100 Imminent
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
The extensively evaluated immunomodulator candidate laquinimod may still have potential in the treatment of neurodegenerative diseases, says Sweden's Active Biotech, despite previous disappointing clinical trials in multiple sclerosis and Huntington's disease conducted by Teva.
Laquinimod fails to impress in a Phase II study in Huntington's disease, adding to a series of clinical trial setbacks over past years for the potential oral immunomodulator.
Eli Lilly, Gilead and Bristol-Myers Squibb can look forward to product indication extensions after getting the OK from the European Medicines Agency’s CHMP. Other companies seeking extensions will be asked for more information.